Entellus Medical, Inc. (NASDAQ:ENTL) VP Timothy B. Petrick sold 2,000 shares of the stock in a transaction on Wednesday, October 4th. The stock was sold at an average price of $20.01, for a total transaction of $40,020.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Timothy B. Petrick also recently made the following trade(s):

  • On Friday, September 22nd, Timothy B. Petrick sold 2,000 shares of Entellus Medical stock. The stock was sold at an average price of $18.00, for a total transaction of $36,000.00.

Entellus Medical, Inc. (NASDAQ:ENTL) traded up 1.25% during midday trading on Friday, reaching $20.30. 127,130 shares of the company were exchanged. Entellus Medical, Inc. has a one year low of $12.31 and a one year high of $21.93. The firm’s 50-day moving average is $18.04 and its 200-day moving average is $18.04. The firm’s market cap is $515.03 million.

Entellus Medical (NASDAQ:ENTL) last posted its earnings results on Thursday, August 3rd. The medical technology company reported ($0.37) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.34) by ($0.03). The business had revenue of $22.10 million during the quarter, compared to analyst estimates of $21.87 million. Entellus Medical had a negative net margin of 41.11% and a negative return on equity of 60.34%. During the same quarter last year, the firm earned ($0.27) earnings per share. Entellus Medical’s revenue was up 18.0% compared to the same quarter last year. On average, equities analysts expect that Entellus Medical, Inc. will post ($1.61) EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This piece was originally posted by Watch List News and is owned by of Watch List News. If you are accessing this piece on another domain, it was copied illegally and reposted in violation of United States & international copyright laws. The correct version of this piece can be read at https://www.watchlistnews.com/entellus-medical-inc-entl-vp-timothy-b-petrick-sells-2000-shares-of-stock/1616026.html.

Several institutional investors have recently modified their holdings of ENTL. Swiss National Bank lifted its stake in shares of Entellus Medical by 98.9% in the first quarter. Swiss National Bank now owns 17,700 shares of the medical technology company’s stock worth $244,000 after buying an additional 8,800 shares during the last quarter. TD Asset Management Inc. acquired a new stake in shares of Entellus Medical in the first quarter worth $279,000. Parametric Portfolio Associates LLC lifted its stake in shares of Entellus Medical by 5.6% in the first quarter. Parametric Portfolio Associates LLC now owns 10,888 shares of the medical technology company’s stock worth $150,000 after buying an additional 573 shares during the last quarter. Royce & Associates LP lifted its stake in shares of Entellus Medical by 288.4% in the first quarter. Royce & Associates LP now owns 167,000 shares of the medical technology company’s stock worth $2,305,000 after buying an additional 124,000 shares during the last quarter. Finally, Vanguard Group Inc. lifted its stake in shares of Entellus Medical by 77.8% in the first quarter. Vanguard Group Inc. now owns 424,823 shares of the medical technology company’s stock worth $5,862,000 after buying an additional 185,833 shares during the last quarter. Institutional investors and hedge funds own 70.24% of the company’s stock.

Several research firms have recently issued reports on ENTL. BidaskClub lowered shares of Entellus Medical from a “buy” rating to a “hold” rating in a research report on Tuesday, August 1st. Piper Jaffray Companies reissued a “buy” rating on shares of Entellus Medical in a research report on Wednesday, July 12th. Finally, Zacks Investment Research raised shares of Entellus Medical from a “sell” rating to a “hold” rating in a research report on Tuesday, August 1st. Three analysts have rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the company’s stock. Entellus Medical presently has a consensus rating of “Hold” and a consensus target price of $21.83.

About Entellus Medical

Entellus Medical, Inc is a medical technology company. The Company is focused on delivering patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis in both adult and pediatric patients. Its three core product lines, XprESS Multi-Sinus Dilation Systems, MiniFESS Surgical Instruments, and FocESS Imaging & Navigation, are designed to enable ear, nose and throat (ENT), physicians to perform a range of procedures in the ENT physician office and to simplify operating room-based treatment.

Insider Buying and Selling by Quarter for Entellus Medical (NASDAQ:ENTL)

Receive News & Ratings for Entellus Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entellus Medical Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.